MedTrace Logo

Absolute Bioavailability Of Bosutinib

NCT02192294 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2014-10-31

No results posted yet for this study

Summary

This is an open-label, randomized, single-dose, one-cohort, two-sequence, two-period crossover study in healthy subjects.

Conditions

  • Healthy

Interventions

DRUG

Oral Bosutinib

a single dose of 500 mg oral bosutinib

DRUG

Intravenous infusion of bosutinib

a single dose of 120 mg of bosutinib intravenous infusion (1 hour)

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • United Kingdom

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02192294 on ClinicalTrials.gov